ADMA Fast ELISA Kit

Sample

Serum, Plasma

Species Reactivity

Human

Intended Use

Enzyme Immunoassay for the Quantitative Determination of Endogenous Asymmetric Dimethylarginine (ADMA) in Serum or Plasma

Storage

On arrival, store the kit at 2-8 °C. Once opened the kit is stable until its expiry date. For stability of prepared reagents refer to Preparation of Reagents.
Do not use components beyond the expiration date shown on the labels. Do not mix various lots of any kit component within an individual assay.

Precision

Intra-Assay-cv (%): 4.9 – 5.4 %
Inter-Assay-cv (%): 4.3 – 9.6 %

Sensitivity

0.03 μmol / l

General Description

The vascular endothelium plays a central role in the regulation of vascular structure and function, mainly due to the formation of endothelium-derived nitric oxide (NO). NO has been named an "endogenous anti-atherogenic molecule" due to its diverse regulatory functions in vascular homeostasis.
NO is formed by the enzyme NO synthetase (NOS) from the amino acid precursor L-arginine. NOS activity can be downregulated by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS.
The effects of ADMA on NO synthesis and NO-mediated pathophysiological processes have been described in numerous experimental studies. Moreover, elevated ADMA levels in plasma have been found in clinical studies including patients with hyper- cholesterolemia, hypertension, chronic heart failure, chronic renal failure and other internal disorders.
Recent prospective and cross-sectional studies indicated that elevated ADMA levels are a risk factor for future cardiovascular events and total mortality. ADMA may have diagnostic relevance as a novel cardiovascular risk marker.

Standard Curve